Advanced Solid Tumor
Conditions
Keywords
advanced solid tumor, Non-small cell lung cancer, Hepatocellular carcinoma, colorectal cancer, cervical cancer
Brief summary
This clinical trial is a multicenter, open, single-arm, non-randomized, dose-escalation and dose-expansion, phase I clinical study in patients with advanced recurrent or metastatic solid tumors.The goal of this study is to evaluate the safety and tolerability of HC010 monotherapy in patients with advanced solid tumors.
Detailed description
This clinical trial is a multicenter, open, single-arm, non-randomized, dose-escalation and dose-expansion, phase I clinical study in patients with advanced recurrent or metastatic solid tumors.The goal of this study is to evaluate the safety and tolerability of HC010 monotherapy in patients with advanced solid tumors.Enrollment is for patients with advanced adult solid tumors (including but not limited to non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, cervical cancer, triple-negative breast cancer, gastric cancer/gastroesophageal junction adenocarcinoma, ovarian cancer, pancreatic cancer, bladder cancer, and renal cancer) who have either failed to respond to standard of care or who are unable to receive/do not have access to standard of care.Subjects received HC010 monotherapy by intravenous infusion every two weeks in 1 cycle of 28 days, and were treated until completion of 2 years of study treatment, disease progression, intolerable toxicity, withdrawal of informed consent, loss to follow-up, death, or fulfillment of other criteria for termination of treatment, whichever occurred first. The primary study endpoints were safety and tolerability, maximum tolerated dose (MTD) and/or recommended dose for phase II clinical studies (RP2D); secondary endpoint indicators included pharmacokinetic indicators, efficacy indicators \[objective response rate (ORR), duration of response (DoR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS)\], immunogenicity indicators such as anti-drug antibody (ADA) and neutralizing antibody (Nab). Exploratory endpoints included the pharmacokinetic (PD) index of HC010, the relationship between peripheral blood T-cell receptor occupancy (RO) and safety and efficacy, as well as the correlation between PD-L1 expression level in tumor tissues and efficacy.
Interventions
DRUGHC010
HC010 Q2W/28d intravenous infusion
Sponsors
HC Biopharma Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Voluntary participation in this clinical trial, understanding and following the research protocol, and voluntarily signing the Informed Consent Form (ICF). 2. Age ≥18 and ≤75, male or female. 3. Participants with histologically or cytologically confirmed diagnosis of advanced solid tumors who have failed standard therapy or for whom no standard therapy is available. 4. Participants must have at least one measurable lesion according to RECIST Version1.1 5. Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1 6. Hepatocellular carcinoma patients with Child-Pugh score ≤ 7 7. Expected survival time is at least 3 months 8. Adequate organ function: neutrophil count≥1.5×109/L,platelet count ≥100×109/L,hemoglobin≥90g/L,alanine aminotransferase and aspartate aminotransferase ≤2.5×upper limit of normal (ULN); patients with hepatocellular carcinoma or concomitant hepatic metastases ≤5.0×ULN, total bilirubin ≤1.5×ULN, renal function and cardiopulmonary function are basically normal. 9. Subjects should provide, whenever possible, freshly obtained or archived tumor tissue sample prior to study treatment that can be used for biomarker analysis 10. Participants of childbearing potential (males and females) must agree to effective contraception for at least 90 days from the time of signing the informed consent form to the time of the last dose; females of childbearing potential must have a negative blood pregnancy test within 7 days prior to the first dose of the HC010
Exclusion criteria
1. Receipt of any interventional clinical trial treatment or other systemic chemotherapy, radiotherapy, etc. within 28 days or 5 half-lives (whichever is shorter) prior to the first dose of the HC010; Receipt of herbal or proprietary Chinese medicine with an anti-tumor indication within 2 weeks prior to the first dose of HC010; 2. Underwent surgery, experienced severe trauma, etc,within 4 weeks prior to the first administration of HC010 ; 3. Receipt of systemic glucocorticoids (prednisone \>10 mg/day or equivalent doses of similar drugs) or other immunosuppressive agents within 2 weeks prior to the first dose of HC010; 4. Receipt of immunomodulatory drugs within 2 weeks prior to the first dose of HC010; 5. Receipt of live attenuated vaccination within 4 weeks prior to the first dose of HC010; 6. Patients who have received biomolecule therapy for anti-programmed death receptor 1 (PD-1)/programmed death ligand (PD-L1), anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4), and anti-vascular endothelial growth factor (VEGF) targets in prior antitumor therapy; 7. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v5.0 Grade≤1; 8. History of immune-related adverse event (irAE) leading to permanent discontinuation from prior immunotherapy ,or grade ≥3 toxicity related to anti-angiogenic therapy from prior anti-angiogenic therapy； 9. Previous allogeneic hematopoietic stem cell transplantation or organ transplantation； 10. Patients with known active brain metastases, or the presence of meningeal metastases, spinal cord compression, or molluscum contagiosum disease； 11. Combination of other malignancies within 5 years prior to the first dose; excludes radically treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, papillary thyroid carcinoma and/or radically resected carcinoma in situ; 12. Patients with active autoimmune disease, or a history of autoimmune disease； 13. Infections: 1) active hepatitis B and C; Note: HBsAg and/or hepatitis B core antibody (HBcAb) positive individuals with HBV DNA ≥500 IU/ml (≥2000 IU/ml in patients with hepatocellular carcinoma) tested within 28 days prior to the initiation of treatment are eligible for inclusion.2) known history of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS); 3) known active syphilis; 4) active tuberculosis; 5) active infection within two weeks prior to first dose of HC010; 14. Unstable systemic disease, including but not limited to, severe cardiovascular disease; pleural effusion, pericardial effusion or peritoneal effusion requiring repeated drainage; 15. Severe bleeding tendencies or coagulation disorders; 16. History of non-infectious pneumonia/interstitial lung disease requiring systemic glucocorticoid therapy; 17. Females who are pregnant or breastfeeding; 18. Inappropriate for this study in the opinion of the investigator; 19. History of systemic hypersensitivity or anaphylaxis to any component of HC010.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of dose-limiting toxicity | 28 days | Incidence of dose-limiting toxicity |
| Adverse events | 2 years | Adverse events |
| serious adverse events | 2 years | serious adverse events |
| Maximum Tolerated Dose | 2 years | Maximum Tolerated Dose |
| Recommended Dose for Phase II Clinical Studies | 2 years | Recommended Dose for Phase II Clinical Studies |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease control rate | 2 years | Disease control rate |
| pharmacokinetics:AUC0-last | 2 years | pharmacokinetics:AUC0-last |
| pharmacokinetics:Cmax | 2 years | pharmacokinetics:Cmax |
| pharmacokinetics:Vd | 2 years | pharmacokinetics:Vd |
| pharmacokinetics:tmax | 2 years | pharmacokinetics:tmax |
| Objective response rate | 2 years | Objective response rate (ORR) |
| duration of response | 2 years | duration of response (DoR) |
| progression-free survival | 2 years | progression-free survival |
| overall survival | 2 years | overall survival |
Countries
China
Contacts
Primary ContactLangxi Zhang, Ph.D
Outcome results
None listed